Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib

References

• GinsburgOBrayFColemanMPThe global burden of women’s cancers: a grand challenge in global healthLancet20173891007184786027814965
   PubMed Web of Science ®Google Scholar
• SenkusEKyriakidesSOhnoSPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526suppl 5v8v3026314782
   PubMed Web of Science ®Google Scholar
• CoatesASWinerEPGoldhirschATailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Ann Oncol20152681533154625939896
   PubMed Web of Science ®Google Scholar
• DenduluriNSomerfieldMREisenASelection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice GuidelineJ Clin Oncol201634202416242727091714
   PubMed Web of Science ®Google Scholar
• CardosoFCostaASenkusE3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)Breast20173124425927927580
   PubMed Web of Science ®Google Scholar
• CardosoFCostaASenkusE3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)Ann Oncol2017281163328177437
   PubMed Web of Science ®Google Scholar
• LambertiniMDel MastroLPescioMCCancer and fertility preservation: international recommendations from an expert meetingBMC Med2016141126728489
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• Leyland-JonesBTrastuzumab: hopes and realitiesLancet Oncol20023313714411902499
   PubMed Web of Science ®Google Scholar
• Del MastroLLambertiniMBighinCTrastuzumab as first-line therapy in HER2-positive metastatic breast cancer patientsExpert Rev Anticancer Ther201212111391140523072512
   PubMed Web of Science ®Google Scholar
• LambertiniMPondéNFSolinasCde AzambujaEAdjuvant trastuzumab: a 10-year overview of its benefitExpert Rev Anticancer Ther2017171617427883296
   PubMed Web of Science ®Google Scholar
• BaselgaJSwainSMNovel anticancer targets: revisiting ERBB2 and discovering ERBB3Nat Rev Cancer20099746347519536107
   PubMed Web of Science ®Google Scholar
• KlapperLNGlatheSVaismanNThe ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factorsProc Natl Acad Sci U S A19999694995500010220407
   PubMed Web of Science ®Google Scholar
• MoasserMMThe oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene200726456469648717471238
   PubMed Web of Science ®Google Scholar
• NagataYLanK-HZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• NahtaRTakahashiTUenoNTHungM-CEstevaFJP27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cellsCancer Res200464113981398615173011
   PubMed Web of Science ®Google Scholar
• NagyPFriedländerETannerMDecreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell lineCancer Res200565247348215695389
   PubMed Web of Science ®Google Scholar
• SaalLHHolmKMaurerMPIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinomaCancer Res20056572554255915805248
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcañaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• ShattuckDLMillerJKCarrawayKLSweeneyCMet receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cellsCancer Res20086851471147718316611
   PubMed Web of Science ®Google Scholar
• FeldingerKGeneraliDKramer-MarekGADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancerOncotarget20145166633664624952873
   PubMedGoogle Scholar
• ParkYHShinH-TJungHHRole of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancerOncotarget2015631320273203826397225
   PubMed Web of Science ®Google Scholar
• HankerABRed BrewerMSheehanJHAn acquired HER2 T798I gatekeeper mutation induces resistance to neratinib in a patient with HER2 mutant-driven breast cancerCancer Discov20177657558528274957
   PubMedGoogle Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• GianniLDafniUGelberRDTreatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trialLancet Oncol201112323624421354370
   PubMed Web of Science ®Google Scholar
• GoldhirschAGelberRDPiccart-GebhartMJ2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialLancet201338298971021102823871490
   PubMed Web of Science ®Google Scholar
• CameronDPiccart-GebhartMJGelberRD11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialLancet2017389100751195120528215665
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• PerezEARomondEHSumanVJFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31J Clin Oncol201129253366337321768458
   PubMed Web of Science ®Google Scholar
• PerezEARomondEHSumanVJTrastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831J Clin Oncol201432333744375225332249
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• SlamonDJEiermannWRobertNJTen year follow-up of the BCIRG-006 trial comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC®T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer patientsSan Antonio Breast Cancer Symposium 2015 Abstract:S5-04
   Google Scholar
• SpielmannMRochéHDelozierTTrastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialJ Clin Oncol200927366129613419917839
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNESequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancerJ Clin Oncol201129344491449722042958
   PubMed Web of Science ®Google Scholar
• PondéNFLambertiniMde AzambujaETwenty years of anti-HER2 therapy-associated cardiotoxicityESMO Open201614e00007327843627
   PubMed Web of Science ®Google Scholar
• PalSKChildsBHPegramMEmergence of nonanthracycline regimens in the adjuvant treatment of breast cancerBreast Cancer Res Treat20101191253219795206
   PubMedGoogle Scholar
• MojaLTagliabueLBalduzziSTrastuzumab containing regimens for early breast cancerCochrane Database Syst Rev20124CD00624322513938
   PubMedGoogle Scholar
• de AzambujaEProcterMJvan VeldhuisenDJTrastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)J Clin Oncol201432202159216524912899
   PubMed Web of Science ®Google Scholar
• ZhangXMunsterPNNew protein kinase inhibitors in breast cancer: afatinib and neratinibExpert Opin Pharmacother20141591277128824787047
   PubMed Web of Science ®Google Scholar
• GossPESmithIEO’ShaughnessyJAdjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trialLancet Oncol2013141889623234763
   PubMed Web of Science ®Google Scholar
• Strasser-WeipplKHorickNSmithIEIdentification of early breast cancer patient cohorts who may benefit from lapatinib therapyEur J Cancer201656859226829011
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMHolmesEBaselgaJAdjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trialJ Clin Oncol201634101034104226598744
   PubMed Web of Science ®Google Scholar
• GaoJSwainSMPertuzumab for the treatment of breast cancer: a safety reviewExpert Opin Drug Saf201615685386326982349
   PubMed Web of Science ®Google Scholar
• SwainSMBaselgaJKimS-BPertuzumab, trastuzumab, and doc-etaxel in HER2-positive metastatic breast cancerN Engl J Med2015372872473425693012
   PubMed Web of Science ®Google Scholar
• MartínezMTPérez-FidalgoJAMartín-MartorellPTreatment of HER2 positive advanced breast cancer with T-DM1: a review of the literatureCrit Rev Oncol Hematol2016979610626318092
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• KropIEKimS-BGonzález-MartínATrastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialLancet Oncol201415768969924793816
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohortLancet Oncol201415664064724657003
   PubMed Web of Science ®Google Scholar
• ValachisAMauriDPolyzosNPChlouverakisGMavroudisDGeorgouliasVTrastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysisBreast201120648549021784637
   PubMed Web of Science ®Google Scholar
• BuzdarAUSumanVJMeric-BernstamFFluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trialLancet Oncol201314131317132524239210
   PubMed Web of Science ®Google Scholar
• IsmaelGHeggRMuehlbauerSSubcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trialLancet Oncol201213986987822884505
   PubMed Web of Science ®Google Scholar
• JackischCKimS-BSemiglazovVSubcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH studyAnn Oncol201526232032525403587
   PubMed Web of Science ®Google Scholar
• JackischCHeggRStroyakovskiyDHannaH phase III randomised study: association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-upEur J Cancer201662627527208905
   PubMed Web of Science ®Google Scholar
• ClavarezzaMPuntoniMGennariADual block with lapatinib and trastuzumab versus single-agent trastuzumab combined with chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trialsClin Cancer Res201622184594460327140927
   PubMed Web of Science ®Google Scholar
• de AzambujaEHolmesAPPiccart-GebhartMLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseLancet Oncol201415101137114625130998
   PubMed Web of Science ®Google Scholar
• SchneeweissAChiaSHickishTPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Ann Oncol20132492278228423704196
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImY-HEfficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialLancet Oncol2012131253222153890
   PubMed Web of Science ®Google Scholar
• GianniLPienkowskiTImY-H5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trialLancet Oncol201617679180027179402
   PubMed Web of Science ®Google Scholar
• KourieHRChaixMGombosAAftimosPAwadaAPharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutationsExpert Opin Drug Metab Toxicol201612894795727284682
   PubMed Web of Science ®Google Scholar
• TiwariSRMishraPAbrahamJNeratinib, a novel HER2-targeted tyrosine kinase inhibitorClin Breast Cancer201616534434827405796
   PubMed Web of Science ®Google Scholar
• ChanADelalogeSHolmesFANeratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncol201617336737726874901
   PubMed Web of Science ®Google Scholar
• AndreyevJRossPDonnellanCGuidance on the management of diarrhoea during cancer chemotherapyLancet Oncol20141510e447e46025186048
   PubMed Web of Science ®Google Scholar
• RugoHSOlopadeOIDeMicheleAAdaptive randomization of veliparib-carboplatin treatment in breast cancerN Engl J Med20163751233427406347
   PubMed Web of Science ®Google Scholar
• ParkJWLiuMCYeeDAdaptive randomization of neratinib in early breast cancerN Engl J Med20163751112227406346
   PubMed Web of Science ®Google Scholar
• JacobsSARobidouxAGarciaJMNSABP FB-7: a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (NþT) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancerSan Antonio Breast Cancer Symposium 2015 Abstract G5-04
   Google Scholar
• JoensuuHEscalating and de-escalating treatment in HER2-positive early breast cancerCancer Treat Rev20175211127866067
   PubMed Web of Science ®Google Scholar
• TolaneySMBarryWTDangCTAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerN Engl J Med2015372213414125564897
   PubMed Web of Science ®Google Scholar
• HanXDiaoLXuYAssociation between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancerAnn Oncol20142561158116424608202
   PubMed Web of Science ®Google Scholar
• Parra-PalauJLMoranchoBPegVEffect of p95HER2/611CTF on the response to trastuzumab and chemotherapyJ Natl Cancer Inst201410611dju29125253614
   PubMedGoogle Scholar
• MontemurroFPratARossiVPotential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancerMol Oncol201481202624075779
   PubMedGoogle Scholar
• Carvajal-HausdorfDESchalperKAPusztaiLMeasurement of domain-specific HER2 (ERBB2) expression may classify benefit from trastuzumab in breast cancerJ Natl Cancer Inst20151078djv13625991002
   PubMedGoogle Scholar
• LeeSBLeeJWYuJHPreoperative serum HER2 extracellular domain levels in primary invasive breast cancerBMC Cancer20141492925491647
   PubMedGoogle Scholar
• Moreno-AspitiaAHillmanDWDyarSHSoluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Cancer2013119152675268223744760
   PubMedGoogle Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• AndréFO’ReganROzgurogluMEverolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialLancet Oncol201415658059124742739
   PubMed Web of Science ®Google Scholar
• HurvitzSAAndreFJiangZCombination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialLancet Oncol201516781682926092818
   PubMed Web of Science ®Google Scholar
• AndréFHurvitzSFasoloAMolecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3J Clin Oncol201634182115212427091708
   PubMed Web of Science ®Google Scholar
• IbrahimEMKazkazGAAl-MansourMMAl-FoheidiMEThe predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysisBreast Cancer Res Treat2015152346347626105797
   PubMedGoogle Scholar
• LoiblSDarb-EsfahaniSHuoberJIntegrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancerClin Cancer Res201622112675268326758558
   PubMedGoogle Scholar
• LoiblSMajewskiIGuarneriVPIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabAnn Oncol20162781519152527177864
   PubMedGoogle Scholar
• LoiSMichielsSLambrechtsDSomatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerJ Natl Cancer Inst20131051396096723739063
   PubMedGoogle Scholar
• PerezEADueckACMcCulloughAEImpact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trialJ Clin Oncol201331172115212223650412
   PubMed Web of Science ®Google Scholar
• Pogue-GeileKLSongNJeongJ-HIntrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialJ Clin Oncol201533121340134725559813
   PubMedGoogle Scholar
• SternHMGardnerHBurzykowskiTPTEN loss is associated with worse outcome in HER2-amplified breast cancer patients but is not associated with trastuzumab resistanceClin Cancer Res20152192065207425649019
   PubMedGoogle Scholar
• ChenYOlopadeOIMYC in breast tumor progressionExpert Rev Anticancer Ther20088101689169818925859
   PubMed Web of Science ®Google Scholar
• PerezEAJenkinsRBDueckACC-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trialJ Clin Oncol201129665165921245420
   PubMed Web of Science ®Google Scholar
• DueckACReinholzMMGeigerXJImpact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831Clin Cancer Res201319205798580723965903
   PubMed Web of Science ®Google Scholar
• BianchiniGGianniLThe immune system and response to HER2- targeted treatment in breast cancerLancet Oncol2014152e58e6824480556
   PubMed Web of Science ®Google Scholar
• KnutsonKLClynesRShreederBImproved survival of HER2+ breast cancer patients treated with trastuzumab and chemotherapy is associated with host antibody immunity against the HER2 intracellular domainCancer Res201676133702371027197192
   PubMed Web of Science ®Google Scholar
• DieciMVMathieuMCGuarneriVPrognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trialsAnn Oncol20152681698170425995301
   PubMedGoogle Scholar
• PerezEABallmanKVTennerKSAssociation of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancerJAMA Oncol201621566426469139
   PubMed Web of Science ®Google Scholar
• Ingold HeppnerBUntchMDenkertCTumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant treated HER2-positive breast cancerClin Cancer Res201622235747575427189162
   PubMedGoogle Scholar
• SolinasCCeppiMLambertiniMTumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: a meta-analysis of randomized controlled trialsCancer Treat Rev20175781528525810
   PubMed Web of Science ®Google Scholar
• LoiSMichielsSSalgadoRTumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnn Oncol20142581544155024608200
   PubMed Web of Science ®Google Scholar
• PerezEAThompsonEABallmanKVGenomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab TrialJ Clin Oncol201533770170825605861
   PubMedGoogle Scholar
• ZardavasDFouadTMPiccartMOptimal adjuvant treatment for patients with HER2-positive breast cancer in 2015Breast201524suppl 2S143S14826255196
   PubMed Web of Science ®Google Scholar